Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: An analysis of real-life data from the BiPe cohorts

• Published in: Pediatric dermatology Vol. 40; no. 5; pp. 835 - 840
• Main Authors: Hanafi, Bochra, Beauchet, Alain, Di Lernia, Vito, Lasek, Audrey, Severino-Freire, Maëlla, Barbarot, Sébastien, Hadj-Rabia, Smail, Phan, Alice, Bursztejn, Anne-Claire, Maruani, Annabel, Chaby, Guillaume, Quiles-Tsimaratos, Nathalie, Phan, Céline, Zitouni, Jinane, Mazereeuw-Hautier, Juliette, Mahé, Emmanuel
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2023; Wiley
• Subjects: Children; Etanercept; Life Sciences; Monoclonal antibodies; Pediatrics; Psoriasis; Remission; children palmoplantar plaque; biologic therapies; psoriasis; psoriasisadolescents; plaque psoriasis; therapies in children
• ISSN: 0736-8046; 1525-1470
• DOI: 10.1111/pde.15393

Palmoplantar plaque psoriasis is a frequent clinical subtype of childhood psoriasis. This study evaluated the effectiveness of biologic therapies in children with palmoplantar plaque psoriasis using data from the two Biological treatments for Pediatric Psoriasis (BiPe) cohorts. Data for all 170 patients included in the BiPe cohorts were analyzed. Data on the effectiveness (PGA, PASI between baseline and 3 months of treatment) of biologic therapies were then compared between children with palmoplantar plaque psoriasis (n = 20) and those with generalized plaque psoriasis (n = 136). Clinical and demographic data were also analyzed. Children in the palmoplantar group were more likely to be male (p = .04), with an earlier age of psoriasis onset (p < .001), and more frequent nail involvement (p < .001). After 3 months of biologic treatment, mean PGA scores were higher in the palmoplantar group than in the generalized plaque psoriasis group (p = .004). In the palmoplantar group, continuation rates were higher for adalimumab than for etanercept or ustekinumab (p = .01). Primary inefficacy was a more frequent reason for stopping biologic therapies in the palmoplantar group (p = .01), and disease remission was less frequent (p = .05). Combined systemic and biologic therapies were more frequently used in palmoplantar plaque psoriasis (p < .001). This study demonstrated the treatment-resistant nature of palmoplantar plaque psoriasis and indicated that adalimumab could be the most effective biologic treatment. Larger studies are needed to allow therapeutic algorithms for palmoplantar plaque psoriasis to be proposed in pediatric psoriasis management guidelines.